Prognostic value of HLA class I expression in patients with oral squamous cell carcinoma

Human leukocyte antigen (HLA) class Ⅰ molecules play a central role in anticancer immunity, but their prognostic value in oral squamous cell carcinoma (OSCC) remains unclear. We examined HLA class I expression in 2 distinct tumor compartments, namely, the tumor center and invasive front, and evaluat...

Full description

Saved in:
Bibliographic Details
Published inCancer science Vol. 111; no. 5; pp. 1491 - 1499
Main Authors Koike, Kazushige, Dehari, Hironari, Shimizu, Shota, Nishiyama, Koyo, Sonoda, Tomoko, Ogi, Kazuhiro, Kobayashi, Junichi, Sasaki, Takanori, Sasaya, Takashi, Tsuchihashi, Kei, Tsukahara, Tomohide, Hasegawa, Tadashi, Torigoe, Toshihiko, Hiratsuka, Hiroyoshi, Miyazaki, Akihiro
Format Journal Article
LanguageEnglish
Published England John Wiley & Sons, Inc 01.05.2020
John Wiley and Sons Inc
Subjects
Antigens
CD8 antigen
Cell density
Cytokeratin
Histocompatibility antigen HLA
HLA class
Invasiveness
Lymphocytes
Lymphocytes T
Medical prognosis
Oral cancer
Oral squamous cell carcinoma
Original
Patients
prognostic factor
Squamous cell carcinoma
Surgery
survival
Tumors
tumor‐infiltrating lymphocyte
tumor-infiltrating lymphocyte
oral squamous cell carcinoma
HLA class
prognostic factor
survival
Online AccessGet full text

Cover

Abstract Human leukocyte antigen (HLA) class Ⅰ molecules play a central role in anticancer immunity, but their prognostic value in oral squamous cell carcinoma (OSCC) remains unclear. We examined HLA class I expression in 2 distinct tumor compartments, namely, the tumor center and invasive front, and evaluated the association between its expression pattern and histopathological status in 137 cases with OSCC. Human leukocyte antigen class Ⅰ expression was graded semiquantitatively as high, low, and negative. At the invasive front of the tumor, HLA class I expression was high in 72 cases (52.6%), low in 44 cases (32.1%), and negative in 21 cases (15.3%). The HLA class I expression in the tumor center was high in 48 cases (35.0%), low in 58 cases (42.4%), and negative in 31 cases (22.6%). The 5‐year overall survival and disease‐specific survival rates were good in cases with high HLA class I expression at the invasive front; however, there was no significant difference in survival based on HLA class I expression in the tumor center. In addition, high HLA class I expression was correlated with high CD8+ T cell density, whereas negative HLA class I expression was correlated with low CD8+ T cell density at the invasive front. These results suggest that it is easier for CD8+ T cells to recognize presented peptides in the case of high HLA class Ⅰ expression at the tumor invasive front and could be a prognostic factor for OSCC. Human leukocyte antigen class Ⅰ expression at the tumor invasive front could be a useful prognostic factor for oral squamous cell carcinoma.
AbstractList Human leukocyte antigen (HLA) class Ⅰ molecules play a central role in anticancer immunity, but their prognostic value in oral squamous cell carcinoma (OSCC) remains unclear. We examined HLA class I expression in 2 distinct tumor compartments, namely, the tumor center and invasive front, and evaluated the association between its expression pattern and histopathological status in 137 cases with OSCC. Human leukocyte antigen class Ⅰ expression was graded semiquantitatively as high, low, and negative. At the invasive front of the tumor, HLA class I expression was high in 72 cases (52.6%), low in 44 cases (32.1%), and negative in 21 cases (15.3%). The HLA class I expression in the tumor center was high in 48 cases (35.0%), low in 58 cases (42.4%), and negative in 31 cases (22.6%). The 5-year overall survival and disease-specific survival rates were good in cases with high HLA class I expression at the invasive front; however, there was no significant difference in survival based on HLA class I expression in the tumor center. In addition, high HLA class I expression was correlated with high CD8+ T cell density, whereas negative HLA class I expression was correlated with low CD8+ T cell density at the invasive front. These results suggest that it is easier for CD8+ T cells to recognize presented peptides in the case of high HLA class Ⅰ expression at the tumor invasive front and could be a prognostic factor for OSCC.Human leukocyte antigen (HLA) class Ⅰ molecules play a central role in anticancer immunity, but their prognostic value in oral squamous cell carcinoma (OSCC) remains unclear. We examined HLA class I expression in 2 distinct tumor compartments, namely, the tumor center and invasive front, and evaluated the association between its expression pattern and histopathological status in 137 cases with OSCC. Human leukocyte antigen class Ⅰ expression was graded semiquantitatively as high, low, and negative. At the invasive front of the tumor, HLA class I expression was high in 72 cases (52.6%), low in 44 cases (32.1%), and negative in 21 cases (15.3%). The HLA class I expression in the tumor center was high in 48 cases (35.0%), low in 58 cases (42.4%), and negative in 31 cases (22.6%). The 5-year overall survival and disease-specific survival rates were good in cases with high HLA class I expression at the invasive front; however, there was no significant difference in survival based on HLA class I expression in the tumor center. In addition, high HLA class I expression was correlated with high CD8+ T cell density, whereas negative HLA class I expression was correlated with low CD8+ T cell density at the invasive front. These results suggest that it is easier for CD8+ T cells to recognize presented peptides in the case of high HLA class Ⅰ expression at the tumor invasive front and could be a prognostic factor for OSCC.
Human leukocyte antigen (HLA) class Ⅰ molecules play a central role in anticancer immunity, but their prognostic value in oral squamous cell carcinoma (OSCC) remains unclear. We examined HLA class I expression in 2 distinct tumor compartments, namely, the tumor center and invasive front, and evaluated the association between its expression pattern and histopathological status in 137 cases with OSCC. Human leukocyte antigen class Ⅰ expression was graded semiquantitatively as high, low, and negative. At the invasive front of the tumor, HLA class I expression was high in 72 cases (52.6%), low in 44 cases (32.1%), and negative in 21 cases (15.3%). The HLA class I expression in the tumor center was high in 48 cases (35.0%), low in 58 cases (42.4%), and negative in 31 cases (22.6%). The 5‐year overall survival and disease‐specific survival rates were good in cases with high HLA class I expression at the invasive front; however, there was no significant difference in survival based on HLA class I expression in the tumor center. In addition, high HLA class I expression was correlated with high CD8+ T cell density, whereas negative HLA class I expression was correlated with low CD8+ T cell density at the invasive front. These results suggest that it is easier for CD8+ T cells to recognize presented peptides in the case of high HLA class Ⅰ expression at the tumor invasive front and could be a prognostic factor for OSCC.
Human leukocyte antigen (HLA) class Ⅰ molecules play a central role in anticancer immunity, but their prognostic value in oral squamous cell carcinoma (OSCC) remains unclear. We examined HLA class I expression in 2 distinct tumor compartments, namely, the tumor center and invasive front, and evaluated the association between its expression pattern and histopathological status in 137 cases with OSCC. Human leukocyte antigen class Ⅰ expression was graded semiquantitatively as high, low, and negative. At the invasive front of the tumor, HLA class I expression was high in 72 cases (52.6%), low in 44 cases (32.1%), and negative in 21 cases (15.3%). The HLA class I expression in the tumor center was high in 48 cases (35.0%), low in 58 cases (42.4%), and negative in 31 cases (22.6%). The 5‐year overall survival and disease‐specific survival rates were good in cases with high HLA class I expression at the invasive front; however, there was no significant difference in survival based on HLA class I expression in the tumor center. In addition, high HLA class I expression was correlated with high CD8 + T cell density, whereas negative HLA class I expression was correlated with low CD8 + T cell density at the invasive front. These results suggest that it is easier for CD8 + T cells to recognize presented peptides in the case of high HLA class Ⅰ expression at the tumor invasive front and could be a prognostic factor for OSCC.
Human leukocyte antigen (HLA) class Ⅰ molecules play a central role in anticancer immunity, but their prognostic value in oral squamous cell carcinoma (OSCC) remains unclear. We examined HLA class I expression in 2 distinct tumor compartments, namely, the tumor center and invasive front, and evaluated the association between its expression pattern and histopathological status in 137 cases with OSCC. Human leukocyte antigen class Ⅰ expression was graded semiquantitatively as high, low, and negative. At the invasive front of the tumor, HLA class I expression was high in 72 cases (52.6%), low in 44 cases (32.1%), and negative in 21 cases (15.3%). The HLA class I expression in the tumor center was high in 48 cases (35.0%), low in 58 cases (42.4%), and negative in 31 cases (22.6%). The 5‐year overall survival and disease‐specific survival rates were good in cases with high HLA class I expression at the invasive front; however, there was no significant difference in survival based on HLA class I expression in the tumor center. In addition, high HLA class I expression was correlated with high CD8+ T cell density, whereas negative HLA class I expression was correlated with low CD8+ T cell density at the invasive front. These results suggest that it is easier for CD8+ T cells to recognize presented peptides in the case of high HLA class Ⅰ expression at the tumor invasive front and could be a prognostic factor for OSCC. Human leukocyte antigen class Ⅰ expression at the tumor invasive front could be a useful prognostic factor for oral squamous cell carcinoma.
Human leukocyte antigen (HLA) class Ⅰ molecules play a central role in anticancer immunity, but their prognostic value in oral squamous cell carcinoma (OSCC) remains unclear. We examined HLA class I expression in 2 distinct tumor compartments, namely, the tumor center and invasive front, and evaluated the association between its expression pattern and histopathological status in 137 cases with OSCC. Human leukocyte antigen class Ⅰ expression was graded semiquantitatively as high, low, and negative. At the invasive front of the tumor, HLA class I expression was high in 72 cases (52.6%), low in 44 cases (32.1%), and negative in 21 cases (15.3%). The HLA class I expression in the tumor center was high in 48 cases (35.0%), low in 58 cases (42.4%), and negative in 31 cases (22.6%). The 5‐year overall survival and disease‐specific survival rates were good in cases with high HLA class I expression at the invasive front; however, there was no significant difference in survival based on HLA class I expression in the tumor center. In addition, high HLA class I expression was correlated with high CD8 + T cell density, whereas negative HLA class I expression was correlated with low CD8 + T cell density at the invasive front. These results suggest that it is easier for CD8 + T cells to recognize presented peptides in the case of high HLA class Ⅰ expression at the tumor invasive front and could be a prognostic factor for OSCC. Human leukocyte antigen class Ⅰ expression at the tumor invasive front could be a useful prognostic factor for oral squamous cell carcinoma.
Human leukocyte antigen (HLA) class Ⅰ molecules play a central role in anticancer immunity, but their prognostic value in oral squamous cell carcinoma (OSCC) remains unclear. We examined HLA class I expression in 2 distinct tumor compartments, namely, the tumor center and invasive front, and evaluated the association between its expression pattern and histopathological status in 137 cases with OSCC. Human leukocyte antigen class Ⅰ expression was graded semiquantitatively as high, low, and negative. At the invasive front of the tumor, HLA class I expression was high in 72 cases (52.6%), low in 44 cases (32.1%), and negative in 21 cases (15.3%). The HLA class I expression in the tumor center was high in 48 cases (35.0%), low in 58 cases (42.4%), and negative in 31 cases (22.6%). The 5-year overall survival and disease-specific survival rates were good in cases with high HLA class I expression at the invasive front; however, there was no significant difference in survival based on HLA class I expression in the tumor center. In addition, high HLA class I expression was correlated with high CD8 T cell density, whereas negative HLA class I expression was correlated with low CD8 T cell density at the invasive front. These results suggest that it is easier for CD8 T cells to recognize presented peptides in the case of high HLA class Ⅰ expression at the tumor invasive front and could be a prognostic factor for OSCC.
Author Nishiyama, Koyo
Tsuchihashi, Kei
Tsukahara, Tomohide
Kobayashi, Junichi
Sasaya, Takashi
Hiratsuka, Hiroyoshi
Dehari, Hironari
Miyazaki, Akihiro
Torigoe, Toshihiko
Hasegawa, Tadashi
Sonoda, Tomoko
Sasaki, Takanori
Ogi, Kazuhiro
Shimizu, Shota
Koike, Kazushige
AuthorAffiliation 4 Department of Surgical Pathology Sapporo Medical University School of Medicine Sapporo Japan
3 Department of Pathology Sapporo Medical University School of Medicine Sapporo Japan
1 Department of Oral Surgery Sapporo Medical University School of Medicine Sapporo Japan
2 Department of Public Health Sapporo Medical University School of Medicine Sapporo Japan
AuthorAffiliation_xml – name: 3 Department of Pathology Sapporo Medical University School of Medicine Sapporo Japan
– name: 4 Department of Surgical Pathology Sapporo Medical University School of Medicine Sapporo Japan
– name: 2 Department of Public Health Sapporo Medical University School of Medicine Sapporo Japan
– name: 1 Department of Oral Surgery Sapporo Medical University School of Medicine Sapporo Japan
Author_xml – sequence: 1
  givenname: Kazushige
  orcidid: 0000-0001-6880-2454
  surname: Koike
  fullname: Koike, Kazushige
  organization: Sapporo Medical University School of Medicine
– sequence: 2
  givenname: Hironari
  surname: Dehari
  fullname: Dehari, Hironari
  email: dehari@sapmed.ac.jp
  organization: Sapporo Medical University School of Medicine
– sequence: 3
  givenname: Shota
  surname: Shimizu
  fullname: Shimizu, Shota
  organization: Sapporo Medical University School of Medicine
– sequence: 4
  givenname: Koyo
  surname: Nishiyama
  fullname: Nishiyama, Koyo
  organization: Sapporo Medical University School of Medicine
– sequence: 5
  givenname: Tomoko
  surname: Sonoda
  fullname: Sonoda, Tomoko
  organization: Sapporo Medical University School of Medicine
– sequence: 6
  givenname: Kazuhiro
  surname: Ogi
  fullname: Ogi, Kazuhiro
  organization: Sapporo Medical University School of Medicine
– sequence: 7
  givenname: Junichi
  surname: Kobayashi
  fullname: Kobayashi, Junichi
  organization: Sapporo Medical University School of Medicine
– sequence: 8
  givenname: Takanori
  surname: Sasaki
  fullname: Sasaki, Takanori
  organization: Sapporo Medical University School of Medicine
– sequence: 9
  givenname: Takashi
  surname: Sasaya
  fullname: Sasaya, Takashi
  organization: Sapporo Medical University School of Medicine
– sequence: 10
  givenname: Kei
  surname: Tsuchihashi
  fullname: Tsuchihashi, Kei
  organization: Sapporo Medical University School of Medicine
– sequence: 11
  givenname: Tomohide
  orcidid: 0000-0002-3678-4359
  surname: Tsukahara
  fullname: Tsukahara, Tomohide
  organization: Sapporo Medical University School of Medicine
– sequence: 12
  givenname: Tadashi
  surname: Hasegawa
  fullname: Hasegawa, Tadashi
  organization: Sapporo Medical University School of Medicine
– sequence: 13
  givenname: Toshihiko
  surname: Torigoe
  fullname: Torigoe, Toshihiko
  organization: Sapporo Medical University School of Medicine
– sequence: 14
  givenname: Hiroyoshi
  surname: Hiratsuka
  fullname: Hiratsuka, Hiroyoshi
  organization: Sapporo Medical University School of Medicine
– sequence: 15
  givenname: Akihiro
  orcidid: 0000-0003-3290-6205
  surname: Miyazaki
  fullname: Miyazaki, Akihiro
  organization: Sapporo Medical University School of Medicine
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32167621$$D View this record in MEDLINE/PubMed
BookMark eNp9kV9rFDEUxYNU7B998AtIwBd9mDbJzUwyL8KyqC0sKKjgW8hk77QpM8k2mWnttzfbrUULNhCSkN89nMM5JHshBiTkNWfHvKwTZ_Mxl6D1M3LAQbaVYqzZu7urqmUg9slhzpeMQSNb-YLsg-CNagQ_ID-_pngeYp68o9d2mJHGnp6uFtQNNmd6RvHXJmHOPgbqA93YyWOYMr3x0wWNyQ40X812jHOmDoeBOpucD3G0L8nz3g4ZX92fR-THp4_fl6fV6svns-ViVTnZ1rqSGiyHxiqUwDmIrgPkupdrKaHG2oGC8tIdE9j2bSfXCNYqZZmudV-7Bo7Ih53uZu5GXLvirrgym-RHm25NtN78-xP8hTmP10YJ0QghisC7e4EUr2bMkxl93maxAUssI0ApKLuFgr59hF7GOYUSzwjZMqmkluJpijU1E6Le-n7zt-8Hw3-qKcD7HeBSzDlh_4BwZra1m1K7uau9sCePWOenUlXcRvbDUxM3fsDb_0ub5eLbbuI3J7S8wQ
CitedBy_id crossref_primary_10_1016_j_tice_2021_101485
crossref_primary_10_1111_tan_15472
crossref_primary_10_1042_BST20210961
crossref_primary_10_3389_fpain_2022_991725
crossref_primary_10_1111_tan_15690
crossref_primary_10_1016_j_omto_2021_06_008
crossref_primary_10_3389_fimmu_2024_1387835
crossref_primary_10_3389_fgene_2022_977902
crossref_primary_10_3389_fgene_2023_1144945
crossref_primary_10_4103_ijohs_ijohs_21_22
crossref_primary_10_1002_cam4_5310
Cites_doi 10.18632/oncotarget.17901
10.1111/j.1349-7006.2006.00317.x
10.1002/(SICI)1097-0215(19971219)74:6<582::AID-IJC4>3.0.CO;2-Q
10.1016/S0009-8981(98)00146-6
10.1186/s13014-018-1099-6
10.18632/oncotarget.7593
10.1186/1471-2407-11-454
10.1016/j.juro.2006.11.082
10.1385/IR:33:2:113
10.4049/jimmunol.176.6.3402
10.1002/ijc.21163
10.1111/j.1349-7006.2007.00558.x
10.1002/cam4.1889
10.1111/jop.12445
10.1158/0008-5472.CAN-04-4621
10.1006/scbi.2001.0404
10.4049/jimmunol.1800242
10.1038/ni1102-999
10.1007/s11605-011-1545-3
10.1038/sj.bjc.6604715
10.1016/S0198-8859(99)00179-2
10.1111/j.1751-2980.2009.00395.x
10.1038/nrc.2016.14
10.1016/j.canlet.2004.11.064
10.1111/eos.12131
10.1016/j.oraloncology.2016.08.003
10.1038/nrc3245
10.1002/ijc.21303
10.1111/j.1349-7006.2009.01329.x
10.1111/j.1440-1827.2012.02789.x
10.1016/j.arcmed.2009.04.004
10.1016/S0065-2776(08)60911-6
10.1002/ijc.24401
10.1016/j.oraloncology.2008.06.002
10.1007/978-3-319-40618-3
10.1016/S0002-9440(10)65321-7
10.1158/1078-0432.67.11.1
ContentType Journal Article
Copyright 2020 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
2020. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2020 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
– notice: 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
– notice: 2020. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
AAYXX
CITATION
NPM
3V.
7X7
7XB
88E
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1111/cas.14388
DatabaseName Wiley Online Library Open Access
CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Journals
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
Publicly Available Content Database
Publicly Available Content Database
CrossRef


PubMed
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate KOIKE et al
EISSN 1349-7006
EndPage 1499
ExternalDocumentID PMC7226222
32167621
10_1111_cas_14388
CAS14388
Genre article
Journal Article
GroupedDBID ---
.3N
.55
.GA
.Y3
05W
0R~
10A
1OC
24P
29B
2WC
31~
36B
3O-
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52W
52X
53G
5GY
5HH
5LA
5VS
66C
7.U
702
7PT
8-0
8-1
8-3
8-4
8-5
8FE
8FH
8UM
930
A01
A03
AAHHS
AAZKR
ABCQN
ABEML
ACCFJ
ACCMX
ACSCC
ACXQS
ADBBV
ADKYN
ADPDF
ADZMN
ADZOD
AEEZP
AENEX
AEQDE
AFBPY
AFEBI
AFFNX
AFKRA
AFPKN
AFZJQ
AIWBW
AJBDE
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AOIJS
AVUZU
BAWUL
BBNVY
BCNDV
BENPR
BFHJK
BHPHI
BY8
CAG
CCPQU
COF
CS3
D-6
D-7
D-E
D-F
DIK
DR2
DU5
E3Z
EBS
EJD
EMB
EMOBN
EX3
F00
F01
F04
F5P
FIJ
GODZA
GROUPED_DOAJ
HCIFZ
HF~
HOLLA
HYE
HZI
HZ~
IAO
IHR
IPNFZ
ITC
IX1
J0M
K.9
K48
KQ8
LC2
LC3
LH4
LK8
LP6
LP7
LW6
M7P
MK4
N04
N05
N9A
O9-
OIG
OK1
OVD
P2P
P2X
P2Z
P4B
P4D
PIMPY
PROAC
Q11
ROL
RPM
RX1
SJN
SUPJJ
SV3
TEORI
UB1
W8V
WIN
WOW
WQJ
WRC
WXI
X7M
XG1
ZXP
~IA
~WT
7X7
88E
8FI
8FJ
AAFWJ
AAYXX
ABUWG
CITATION
FYUFA
HMCUK
M1P
PHGZM
PHGZT
PSQYO
UKHRP
NPM
3V.
7XB
8FK
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
AZQEC
DWQXO
GNUQQ
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c4958-483a136a7e431132bb3e18f4d4435e5c3738f48b02e9f9b4de3aa77a0858f5c63
IEDL.DBID 7X7
ISSN 1347-9032
1349-7006
IngestDate Thu Aug 21 18:21:31 EDT 2025
Fri Jul 11 01:23:13 EDT 2025
Wed Aug 13 08:40:41 EDT 2025
Wed Aug 13 11:23:06 EDT 2025
Wed Feb 19 02:31:00 EST 2025
Thu Apr 24 22:52:25 EDT 2025
Tue Jul 01 01:31:08 EDT 2025
Wed Jan 22 16:33:28 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords tumor-infiltrating lymphocyte
oral squamous cell carcinoma
HLA class
prognostic factor
survival
Language English
License Attribution-NonCommercial
2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4958-483a136a7e431132bb3e18f4d4435e5c3738f48b02e9f9b4de3aa77a0858f5c63
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-3290-6205
0000-0002-3678-4359
0000-0001-6880-2454
OpenAccessLink https://www.proquest.com/docview/2406502256?pq-origsite=%requestingapplication%
PMID 32167621
PQID 2406502256
PQPubID 4378882
PageCount 9
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_7226222
proquest_miscellaneous_2377337793
proquest_journals_2490474842
proquest_journals_2406502256
pubmed_primary_32167621
crossref_primary_10_1111_cas_14388
crossref_citationtrail_10_1111_cas_14388
wiley_primary_10_1111_cas_14388_CAS14388
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate May 2020
PublicationDateYYYYMMDD 2020-05-01
PublicationDate_xml – month: 05
  year: 2020
  text: May 2020
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Tokyo
– name: Hoboken
PublicationTitle Cancer science
PublicationTitleAlternate Cancer Sci
PublicationYear 2020
Publisher John Wiley & Sons, Inc
John Wiley and Sons Inc
Publisher_xml – name: John Wiley & Sons, Inc
– name: John Wiley and Sons Inc
References 2009; 45
2019; 8
2017; 8
2009; 40
2006; 97
2002; 12
2004; 25
2018; 202
2005; 117
2009
2006; 176
2011; 11
2002; 3
2005; 65
2008; 99
2011; 15
2007; 98
2006; 118
1998; 278
2013; 5
2012; 12
2016; 16
2016; 7
2009; 10
1997; 74
2007; 177
2000; 74
2005; 228
2000; 61
1999; 154
2009; 100
2017
2016; 61
2015
2005; 2
2014; 122
2005; 11
2009; 125
2016; 45
2012; 62
2018; 13
e_1_2_10_23_1
e_1_2_10_24_1
e_1_2_10_22_1
e_1_2_10_42_1
e_1_2_10_20_1
e_1_2_10_41_1
e_1_2_10_40_1
Abbas AK (e_1_2_10_21_1) 2009
e_1_2_10_2_1
e_1_2_10_4_1
e_1_2_10_18_1
e_1_2_10_3_1
e_1_2_10_19_1
e_1_2_10_6_1
e_1_2_10_16_1
e_1_2_10_39_1
e_1_2_10_5_1
e_1_2_10_17_1
e_1_2_10_38_1
e_1_2_10_8_1
e_1_2_10_14_1
e_1_2_10_37_1
e_1_2_10_7_1
e_1_2_10_15_1
e_1_2_10_12_1
e_1_2_10_35_1
e_1_2_10_9_1
e_1_2_10_13_1
e_1_2_10_34_1
e_1_2_10_10_1
e_1_2_10_33_1
e_1_2_10_11_1
e_1_2_10_32_1
e_1_2_10_31_1
e_1_2_10_30_1
Bubeník J (e_1_2_10_28_1) 2004; 25
Russell S (e_1_2_10_36_1) 2013; 5
e_1_2_10_29_1
e_1_2_10_27_1
e_1_2_10_25_1
e_1_2_10_26_1
References_xml – volume: 97
  start-page: 1374
  year: 2006
  end-page: 1380
  article-title: Prognostic significance of HLA class I expression in osteosarcoma defined by anti‐pan HLA class I monoclonal antibody, EMR8‐5
  publication-title: Cancer Sci
– volume: 25
  start-page: 487
  year: 2004
  end-page: 491
  article-title: MHC class I down‐regulation: tumor escape from immune surveillance?
  publication-title: Int J Oncol
– year: 2009
– volume: 61
  start-page: 159
  year: 2016
  end-page: 165
  article-title: Telltale tumor infiltrating lymphocytes (TIL) in oral, head & neck cancer
  publication-title: Oral Oncol
– volume: 10
  start-page: 265
  year: 2009
  end-page: 271
  article-title: Association of HLA class II alleles with chronic atrophic gastritis and gastric carcinoma
  publication-title: J Dig Dis
– volume: 2
  start-page: 113
  year: 2005
  end-page: 133
  article-title: Human leukocyte antigen (HLA) class I defects in head and neck cancer
  publication-title: Immunol Res
– volume: 98
  start-page: 1424
  year: 2007
  end-page: 1430
  article-title: HLA class I antigen expression is associated with a favorable prognosis in early stage non‐small cell lung cancer
  publication-title: Cancer Sci
– volume: 65
  start-page: 3937
  year: 2005
  end-page: 3941
  article-title: Intratumoral T‐cell infiltrates and MHC class I expression in patients with stage IV melanoma
  publication-title: Cancer Res
– volume: 118
  start-page: 6
  year: 2006
  end-page: 10
  article-title: Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis
  publication-title: Int J Cancer
– volume: 12
  start-page: 3
  year: 2002
  end-page: 13
  article-title: HLA class I antigen abnormalities and immune escape by malignant cells
  publication-title: Semin Cancer Biol
– volume: 8
  start-page: 44418
  year: 2017
  end-page: 44433
  article-title: Characterization of tumor‐associated T‐lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma
  publication-title: Oncotarget
– volume: 202
  start-page: 278
  year: 2018
  end-page: 291
  article-title: Composition and clinical impact of the immunologic tumor microenvironment in oral squamous cell carcinoma
  publication-title: J Immunol
– volume: 45
  start-page: 635
  year: 2016
  end-page: 639
  article-title: Regulatory T cells in oral squamous cell carcinoma
  publication-title: J Oral Pathol Med
– volume: 5
  start-page: 24
  year: 2013
  article-title: Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma
  publication-title: Head Neck Oncol
– volume: 117
  start-page: 248
  year: 2005
  end-page: 255
  article-title: Total loss of MHC class I is an independent indicator of good prognosis in breast cancer
  publication-title: Int J Cancer
– volume: 100
  start-page: 2331
  year: 2009
  end-page: 2334
  article-title: Human leukocyte antigen class I down‐regulation in muscle‐invasive bladder cancer: its association with clinical characteristics and survival after cystectomy
  publication-title: Cancer Sci
– volume: 177
  start-page: 1269
  year: 2007
  end-page: 1272
  article-title: Down‐regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma
  publication-title: J Urol
– volume: 99
  start-page: 1462
  year: 2008
  end-page: 1467
  article-title: Downregulation of HLA class I molecules in the tumor is associated with a poor prognosis in patients with esophageal squamous cell carcinoma
  publication-title: Br J Cancer
– volume: 228
  start-page: 155
  year: 2005
  end-page: 161
  article-title: Mechanisms of immune evasion of human neuroblastoma
  publication-title: Cancer Lett
– volume: 11
  start-page: 67
  year: 2005
  end-page: 72
  article-title: HLA class I antigen down‐regulation in primary ovary carcinoma lesions: association with disease stage
  publication-title: Clin Cancer Res
– volume: 122
  start-page: 202
  year: 2014
  end-page: 209
  article-title: Expression of CD163, interleukin‐10, and interferon‐gamma in oral squamous cell carcinoma: mutual relationships and prognostic implications
  publication-title: Eur J Oral Sci
– volume: 125
  start-page: 367
  year: 2009
  end-page: 373
  article-title: Interferon‐γ reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor‐associated macrophages
  publication-title: Int J Cancer
– volume: 15
  start-page: 1336
  year: 2011
  end-page: 1343
  article-title: Prognostic significance of HLA class I expressing in gastric carcinoma defined by monoclonal anti‐pan HLA class I antibody, EMR8‐5
  publication-title: J Gastrointest Surg
– volume: 45
  start-page: 309
  year: 2009
  end-page: 316
  article-title: Global epidemiology of oral and oropharyngeal cancer
  publication-title: Oral Oncol
– volume: 12
  start-page: 298
  year: 2012
  end-page: 306
  article-title: The immune contexture in human tumours: impact on clinical outcome
  publication-title: Nat Rev Cancer
– volume: 154
  start-page: 745
  year: 1999
  end-page: 754
  article-title: Down‐regulation of HLA class I antigen‐processing molecules in malignant melanoma: association with disease progression
  publication-title: Am J Pathol
– volume: 176
  start-page: 3402
  year: 2006
  end-page: 3409
  article-title: Role of antigen‐processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL
  publication-title: J Immunol
– volume: 278
  start-page: 185
  year: 1998
  end-page: 192
  article-title: Comparative evaluation of automated systems in immunohistochemistry
  publication-title: Clin Chim Acta
– volume: 7
  start-page: 12024
  year: 2016
  end-page: 12034
  article-title: CD274/PD‐L1 gene amplification and PD‐L1 protein expression are common events in squamous cell carcinoma of the oral cavity
  publication-title: Oncotarget
– volume: 74
  start-page: 181
  year: 2000
  end-page: 273
  article-title: Escape of human solid tumors from T‐cell recognition: molecular mechanisms and functional significance
  publication-title: Adv Immunol
– volume: 11
  start-page: 454
  year: 2011
  article-title: Clinical implication of HLA class I expression in breast cancer
  publication-title: BMC Cancer
– volume: 3
  start-page: 999
  year: 2002
  end-page: 1005
  article-title: Natural selection of tumor variants in the generation of “tumor escape” phenotypes
  publication-title: Nat Immunol
– volume: 62
  start-page: 303
  year: 2012
  end-page: 308
  article-title: Establishment of a monoclonal anti‐pan HLA class I antibody suitable for immunostaining of formalin‐fixed tissue: unusually high frequency of down‐regulation in breast cancer tissues
  publication-title: Pathol Int
– volume: 61
  start-page: 397
  year: 2000
  end-page: 407
  article-title: Biochemical analysis of HLA class I subunits expression in breast cancer tissues
  publication-title: Hum Immunol
– year: 2017
– volume: 74
  start-page: 582
  year: 1997
  end-page: 587
  article-title: Expression and prognostic significance of immunoregulatory molecules in esophageal cancer
  publication-title: Int J Cancer
– volume: 13
  start-page: 157
  year: 2018
  article-title: Prognostic significance of tumor‐infiltrating lymphocytes in patients with operable tongue cancer
  publication-title: Radiat Oncol
– volume: 8
  start-page: 80
  year: 2019
  end-page: 93
  article-title: Tumor‐infiltrating CD8⁺ T‐cell density is an independent prognostic marker for oral squamous cell carcinoma
  publication-title: Cancer Med
– volume: 40
  start-page: 256
  year: 2009
  end-page: 263
  article-title: Downregulation of HLA class I molecules in primary oral squamous cell carcinomas and cell lines
  publication-title: Arch Med Res
– volume: 16
  start-page: 131
  issue: 3
  year: 2016
  end-page: 144
  article-title: Antitumour actions of interferons: implications for cancer therapy
  publication-title: Nat Rev Cancer
– year: 2015
– ident: e_1_2_10_34_1
  doi: 10.18632/oncotarget.17901
– ident: e_1_2_10_23_1
  doi: 10.1111/j.1349-7006.2006.00317.x
– ident: e_1_2_10_2_1
– ident: e_1_2_10_9_1
  doi: 10.1002/(SICI)1097-0215(19971219)74:6<582::AID-IJC4>3.0.CO;2-Q
– ident: e_1_2_10_24_1
  doi: 10.1016/S0009-8981(98)00146-6
– ident: e_1_2_10_37_1
  doi: 10.1186/s13014-018-1099-6
– ident: e_1_2_10_33_1
  doi: 10.18632/oncotarget.7593
– ident: e_1_2_10_18_1
  doi: 10.1186/1471-2407-11-454
– ident: e_1_2_10_14_1
  doi: 10.1016/j.juro.2006.11.082
– ident: e_1_2_10_30_1
  doi: 10.1385/IR:33:2:113
– ident: e_1_2_10_7_1
  doi: 10.4049/jimmunol.176.6.3402
– ident: e_1_2_10_39_1
  doi: 10.1002/ijc.21163
– ident: e_1_2_10_11_1
  doi: 10.1111/j.1349-7006.2007.00558.x
– ident: e_1_2_10_20_1
  doi: 10.1002/cam4.1889
– ident: e_1_2_10_31_1
  doi: 10.1111/jop.12445
– ident: e_1_2_10_26_1
  doi: 10.1158/0008-5472.CAN-04-4621
– ident: e_1_2_10_5_1
  doi: 10.1006/scbi.2001.0404
– ident: e_1_2_10_8_1
  doi: 10.4049/jimmunol.1800242
– ident: e_1_2_10_27_1
  doi: 10.1038/ni1102-999
– ident: e_1_2_10_16_1
  doi: 10.1007/s11605-011-1545-3
– volume: 25
  start-page: 487
  year: 2004
  ident: e_1_2_10_28_1
  article-title: MHC class I down‐regulation: tumor escape from immune surveillance?
  publication-title: Int J Oncol
– volume: 5
  start-page: 24
  year: 2013
  ident: e_1_2_10_36_1
  article-title: Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma
  publication-title: Head Neck Oncol
– ident: e_1_2_10_17_1
  doi: 10.1038/sj.bjc.6604715
– ident: e_1_2_10_29_1
  doi: 10.1016/S0198-8859(99)00179-2
– ident: e_1_2_10_42_1
  doi: 10.1111/j.1751-2980.2009.00395.x
– ident: e_1_2_10_40_1
  doi: 10.1038/nrc.2016.14
– ident: e_1_2_10_6_1
  doi: 10.1016/j.canlet.2004.11.064
– ident: e_1_2_10_35_1
  doi: 10.1111/eos.12131
– ident: e_1_2_10_32_1
  doi: 10.1016/j.oraloncology.2016.08.003
– ident: e_1_2_10_38_1
  doi: 10.1038/nrc3245
– ident: e_1_2_10_13_1
  doi: 10.1002/ijc.21303
– ident: e_1_2_10_15_1
  doi: 10.1111/j.1349-7006.2009.01329.x
– ident: e_1_2_10_19_1
  doi: 10.1111/j.1440-1827.2012.02789.x
– ident: e_1_2_10_22_1
  doi: 10.1016/j.arcmed.2009.04.004
– ident: e_1_2_10_4_1
  doi: 10.1016/S0065-2776(08)60911-6
– ident: e_1_2_10_41_1
  doi: 10.1002/ijc.24401
– ident: e_1_2_10_3_1
  doi: 10.1016/j.oraloncology.2008.06.002
– ident: e_1_2_10_25_1
  doi: 10.1007/978-3-319-40618-3
– ident: e_1_2_10_10_1
  doi: 10.1016/S0002-9440(10)65321-7
– volume-title: Basic Immunology: Functions and Disorders of the Immune System
  year: 2009
  ident: e_1_2_10_21_1
– ident: e_1_2_10_12_1
  doi: 10.1158/1078-0432.67.11.1
SSID ssj0036494
Score 2.3670707
Snippet Human leukocyte antigen (HLA) class Ⅰ molecules play a central role in anticancer immunity, but their prognostic value in oral squamous cell carcinoma (OSCC)...
SourceID pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1491
SubjectTerms Antigens
CD8 antigen
Cell density
Cytokeratin
Histocompatibility antigen HLA
HLA class
Invasiveness
Lymphocytes
Lymphocytes T
Medical prognosis
Oral cancer
Oral squamous cell carcinoma
Original
Patients
prognostic factor
Squamous cell carcinoma
Surgery
survival
Tumors
tumor‐infiltrating lymphocyte
SummonAdditionalLinks – databaseName: Wiley Online Library - Core collection (SURFmarket)
  dbid: DR2
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dSxwxEB_EB-mLH60f6xdp8cGXldtNsrnFp-PwuEotpSrcg7Ak2Sw9qnvq3YH0r-9M9gOvVhDfFjILyWQm-WUy-Q3AURwlUvNchjpKi1AUBtdBaWyoE66s49pwX6bz4nsyvBbnIzlagtPmLUzFD9EG3Mgz_HpNDq7N9JmTU0kwqt1ND30pV4sA0c-WOoonIq0K2goVph0e16xClMXT_rm4F70AmC_zJJ_jV78BDdbgpul6lXfy-2Q-Myf2zz-sju8c2zqs1sCU9SpL2oAlV36ElYv66v0TjH48TigpD5sZMYQ7NinY8FuPWcLf7CtzT3VObcnGJav5WqeMAr2MaADY9GGuKdDA6LKAWSpiVE7u9CZcD86u-sOwLssQWjxN-fCjRoVr5RB84GHWGO6ibiFygdDLSUtcSYXomk7s0iI1Iscp10ppBHfdQtqEb8FyOSndDrCOi3KcnMjgOUloJ1MTOS2S3MWC5yqxARw3E5TZmrOcSmfcZs3ZBTWVeU0F8KUVva-IOv4ntN_Mclb76jQjTCMRysjklea0I4hxNQ7gc9uMTkjK0qVDvWUxV4oTdSMPYLuymbYTHN0Bd5woALVgTa0AEXwvtpTjX57oWyE2RvyGWvDG8vq4sn7v0n_svl10Dz7EFDvwyZv7sDx7nLsDBFgzc-g96S9iqiFd
  priority: 102
  providerName: Wiley-Blackwell
Title Prognostic value of HLA class I expression in patients with oral squamous cell carcinoma
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcas.14388
https://www.ncbi.nlm.nih.gov/pubmed/32167621
https://www.proquest.com/docview/2406502256
https://www.proquest.com/docview/2490474842
https://www.proquest.com/docview/2377337793
https://pubmed.ncbi.nlm.nih.gov/PMC7226222
Volume 111
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9wwEB7xkKpeqpa-0sLKrTj0EnXj5-ZUbRFoiwCtoEh7i2zHUZHaBFiQ-PnMeL0pK0ovUST7kMw4nm_Gk-8D2OWFVlbUKrdF2eSycbgPKudzq4XxQVgnokzn8YmenMvDmZqlgts8tVUu98S4Udedpxr5V4o8CgOO0t8ur3JSjaLT1SShsQ6bRF1GLV1m1idcQstyIWorTV4OBU_MQtTJQ4JipPw9Wo1Hj0Dm417Jhxg2BqGDl_AioUc2Xrj7FayFdgueHafz8dcwm1531DmHw4xovAPrGjY5GjNPIJn9YOEuNb627KJliVR1zqgay-hffTa_urVUDWBU0WeelIba7o99A-cH-z_3JnnSTsg9pjyxRmgLoa0JiBAw43ROhGLUyFoiPgrKE6FRI0duyEPZlE7W6BdrjEUENmqU1-ItbLRdG94DG4aiRusVDpMZaYMqXRGs1HXgUtRG-wy-LC1Y-UQsTvoWv6tlgoHGrqKxM_jcT71csGn8a9L20g1V-qDm1V_3PzFcDiXRovIMPvXD-KWQsWwb0G4VF8YI4lcUGbxbOLV_CIFrFsNCkYFZcXc_gVi4V0fai1-RjdsggEWQhVaIC-Pp96r2xmfx5sP_X_AjPOeU1Meuym3YuLm-DTuIfG7cANa5nA7iIh_A5vf9k-npIFYR6HrK7wGKPgWQ
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VVAIuiDeGAgsCiYtFvM_4gFAorRKaRBW0Um5md70WlVq7bVoBf4rfyIwfgaiUW2-RdhXZs7M738yOvw_gFU-0siJXsU3SIpaFw3NQOR9bLYwPwjpRy3ROZ3q0Lz_N1XwNfnXfwlBbZXcm1gd1Xnmqkb-lyKMw4Cj9_vgkJtUoul3tJDQat9gJP79jyrZ4N_6I6_ua8-2tvc1R3KoKxB6Tgbp6ZhOhrQkYOzEXc06EZFDIXCJyCMoT1U8hB67PQ1qkTub4xNYYi9hkUCivBf7vNViXAlOZHqx_2Jrtfu7OfqFl2sjoShOnfcFbLiPqHSIJM9IaH6xGwAuw9mJ35t-ouQ5727fhVotX2bBxsDuwFsq7cH3a3sjfg_nuaUW9ejjMiDg8sKpgo8mQeYLlbMzCj7bVtmQHJWtpXBeM6r-M2AHY4uTcUv2B0R0C86RtVFZH9j7sX4ldH0CvrMrwCFg_JDlaL3GYPkkbVOqSYKXOA5ciN9pH8KazYOZbKnNS1DjMupQGjZ3Vxo7g5XLqccPf8a9JG90yZO0WXmR_HO6S4bQviYiVR_BiOYx7k4xly4B2y7gwRhCjo4jgYbOoy4cQuEswECURmJXlXk4g3u_VkfLgW83_bRAyI6xDK9SOcfl7ZZvDL_WPx_9_wedwY7Q3nWST8WznCdzkVFKoezo3oHd2eh6eIu46c89aZ2fw9ar31286Uz4i
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIlVcUHk2bQGDQOISdeNHvDkgtGpZ7dKHKkGlvQXbcUQlSNpuq8Jf66_rjPOAVSm33iLZipzxjOfhyfcBvOVJqowoVGySrIxlafEcVNbFJhXaeWGsCDSd-wfp5Eh-nqnZElx1_8JQW2V3JoaDuqgd1ci3yPModDgq3SrbtojDnfHHk9OYGKToprWj02hUZNf_vsT0bf5huoN7_Y7z8aev25O4ZRiIHSYGoZJmEpEa7dGPYl5mrfDJsJSFxCjCK0ewP6Uc2gH3WZlZWeDqjdYG45RhqVwq8L334L4WKiEb07M-2ROpzBpCXanjbCB4i2pEXUREZkas48NFX3gjwL3Zp_l3_Bwc4HgVHraRKxs1qvYIlnz1GFb227v5JzA7PKupaw-HGUGIe1aXbLI3Yo4CdDZl_lfbdFux44q1gK5zRpVgRjgBbH56YagSweg2gTliOarqn-YpHN2JVJ_BclVXfg3YwCcFSi-xmEhJ41VmE29kWnguRaFTF8H7ToK5a0HNiVvjR94lNyjsPAg7gjf91JMGyeNfkza7bchbY57nf1TvluFsIAmSlUfwuh9GKyVhmcqj3HIutBaE7SgieN5sar8IgfaCLimJQC9sdz-BEMAXR6rj7wEJXGPwjAEeSiEoxu3flW-PvoSH9f9_4CtYQavK96YHuxvwgFNtITR3bsLy-dmFf4EB2Ll9GTSdwbe7Nq1rn_hA8g
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+value+of+HLA+class+I+expression+in+patients+with+oral+squamous+cell+carcinoma&rft.jtitle=Cancer+science&rft.au=Koike%2C+Kazushige&rft.au=Dehari%2C+Hironari&rft.au=Shimizu%2C+Shota&rft.au=Nishiyama%2C+Koyo&rft.date=2020-05-01&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.issn=1347-9032&rft.eissn=1349-7006&rft.volume=111&rft.issue=5&rft.spage=1491&rft.epage=1499&rft_id=info:doi/10.1111%2Fcas.14388&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1347-9032&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1347-9032&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1347-9032&client=summon